Several recent papers have proven the therapeutic potential of targeted inhibition of bromodomain-containing proteins using hematological malignancies including severe myeloid leukemia (AML) [1 2 and multiple myeloma (MM) [3 4 The prospective proteins participate in the bromodomain and further terminal (BET) category of adaptors (BRD2 BRD3 BRD4 and BRDT) that have acetyl-lysine recognition motifs or… Continue reading Several recent papers have proven the therapeutic potential of targeted inhibition